Document -
NICE recommends access to AbbVie’s VENCLYXTO®▼ (venetoclax) to treat most common form of adult leukaemia in England via Cancer Drugs Fund
Today the National Institute for Health and Care Excellence (NICE) has issued a final appraisal determination (FAD) recommending that AbbVie’s VENCLYXTO® (venetoclax) is made available to NHS patients with difficult-to-treat types of chronic lymphocytic leukaemia (CLL) via the Cancer Drugs Fund (CDF), providing conditions of the managed access agreement are followed.
- License:
- All rights reserved
The Content may only be used by Mynewsdesk. It is thus not permissible for anyone else to download, copy, distribute or otherwise use the Content (other than for private use to the extent permitted by law).
- File format: